198 related articles for article (PubMed ID: 26972881)
1. Factors associated with treatment success and death in cases with multidrug-resistant tuberculosis in Bulgaria, 2009-2010.
Milanov V; Falzon D; Zamfirova M; Varleva T; Bachiyska E; Koleva A; Dara M
Int J Mycobacteriol; 2015 Jun; 4(2):131-7. PubMed ID: 26972881
[TBL] [Abstract][Full Text] [Related]
2. Treatment outcomes of patients with multidrug-resistant and extensively drug resistant tuberculosis in Hunan Province, China.
Alene KA; Yi H; Viney K; McBryde ES; Yang K; Bai L; Gray DJ; Clements ACA; Xu Z
BMC Infect Dis; 2017 Aug; 17(1):573. PubMed ID: 28814276
[TBL] [Abstract][Full Text] [Related]
3. Predictors of recurrence of multidrug-resistant and extensively drug-resistant tuberculosis.
Blöndal K; Viiklepp P; Guðmundsson LJ; Altraja A
Int J Tuberc Lung Dis; 2012 Sep; 16(9):1228-33. PubMed ID: 22748131
[TBL] [Abstract][Full Text] [Related]
4. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis.
Kwon YS; Kim YH; Suh GY; Chung MP; Kim H; Kwon OJ; Choi YS; Kim K; Kim J; Shim YM; Koh WJ
Clin Infect Dis; 2008 Aug; 47(4):496-502. PubMed ID: 18611154
[TBL] [Abstract][Full Text] [Related]
5. Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis.
Kim HR; Hwang SS; Kim HJ; Lee SM; Yoo CG; Kim YW; Han SK; Shim YS; Yim JJ
Clin Infect Dis; 2007 Nov; 45(10):1290-5. PubMed ID: 17968823
[TBL] [Abstract][Full Text] [Related]
6. Early detection of multidrug- and pre-extensively drug-resistant tuberculosis from smear-positive sputum by direct sequencing.
Chen J; Peng P; Du Y; Ren Y; Chen L; Rao Y; Wang W
BMC Infect Dis; 2017 Apr; 17(1):300. PubMed ID: 28438132
[TBL] [Abstract][Full Text] [Related]
7. Treatment efficacy of drug-resistant tuberculosis in Bashkortostan, Russia: A retrospective cohort study.
Yunusbaeva M; Borodina L; Alekseev P; Davydov R; Yunusbaev U; Sharipov R; Bilalov F; Yunusbayev B
Int J Infect Dis; 2019 Apr; 81():203-209. PubMed ID: 30794942
[TBL] [Abstract][Full Text] [Related]
8. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.
Park SK; Kim JH; Kang H; Cho JS; Smego RA
Int J Infect Dis; 2009 Mar; 13(2):170-5. PubMed ID: 18768342
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of drug-resistant tuberculosis treatment outcome in Portugal, 2000-2016.
Oliveira O; Gaio R; Correia-Neves M; Rito T; Duarte R
PLoS One; 2021; 16(4):e0250028. PubMed ID: 33878119
[TBL] [Abstract][Full Text] [Related]
10. Comparison of bacteriological conversion and treatment outcomes among MDR-TB patients with and without diabetes in Mexico: Preliminary data.
Muñoz-Torrico M; Caminero Luna J; Migliori GB; D'Ambrosio L; Carrillo-Alduenda JL; Villareal-Velarde H; Torres-Cruz A; Flores-Ergara H; Martínez-Mendoza D; García-Sancho C; Centis R; Salazar-Lezama MÁ; Pérez-Padilla R
Rev Port Pneumol (2006); 2017; 23(1):27-30. PubMed ID: 28043788
[TBL] [Abstract][Full Text] [Related]
11. Characteristics and treatment outcomes of patients with MDR and XDR tuberculosis in a TB referral hospital in Beijing: a 13-year experience.
Liu CH; Li L; Chen Z; Wang Q; Hu YL; Zhu B; Woo PC
PLoS One; 2011 Apr; 6(4):e19399. PubMed ID: 21559362
[TBL] [Abstract][Full Text] [Related]
12. Highly successful treatment outcome of multidrug-resistant and genetic diversity of multidrug-resistant Mycobacterium tuberculosis strains in Rwanda.
Muvunyi CM; Ngabonziza JCS; Uwimana I; Harelimana JD; Mucyo Y; Sebatunzi OR; Muvunyi TZ; Seruyange E; Masaisa F; Mazarati JB; Gasana M
Trop Med Int Health; 2019 Jul; 24(7):879-887. PubMed ID: 31066112
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for extensive drug resistance in multidrug-resistant tuberculosis cases: a case-case study.
Guglielmetti L; Veziris N; Aubry A; Brossier F; Bernard C; Sougakoff W; Jarlier V; Robert J
Int J Tuberc Lung Dis; 2018 Jan; 22(1):54-59. PubMed ID: 29297426
[TBL] [Abstract][Full Text] [Related]
14. Adverse Effects and Choice between the Injectable Agents Amikacin and Capreomycin in Multidrug-Resistant Tuberculosis.
Arnold A; Cooke GS; Kon OM; Dedicoat M; Lipman M; Loyse A; Chis Ster I; Harrison TS
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28696239
[TBL] [Abstract][Full Text] [Related]
15. Long-term treatment outcomes in patients with multidrug-resistant tuberculosis.
Maier C; Chesov D; Schaub D; Kalsdorf B; Andres S; Friesen I; Reimann M; Lange C
Clin Microbiol Infect; 2023 Jun; 29(6):751-757. PubMed ID: 36842637
[TBL] [Abstract][Full Text] [Related]
16. Unacceptable treatment outcomes and associated factors among India's initial cohorts of multidrug-resistant tuberculosis (MDR-TB) patients under the revised national TB control programme (2007-2011): Evidence leading to policy enhancement.
Parmar MM; Sachdeva KS; Dewan PK; Rade K; Nair SA; Pant R; Khaparde SD
PLoS One; 2018; 13(4):e0193903. PubMed ID: 29641576
[TBL] [Abstract][Full Text] [Related]
17. Prevalence, associated factors, outcomes and transmission of extensively drug-resistant tuberculosis among multidrug-resistant tuberculosis patients in São Paulo, Brazil: a cross-sectional study.
Gallo JF; Pinhata JMW; Simonsen V; Galesi VMN; Ferrazoli L; Oliveira RS
Clin Microbiol Infect; 2018 Aug; 24(8):889-895. PubMed ID: 29175351
[TBL] [Abstract][Full Text] [Related]
18. Multidrug-resistant tuberculosis in Uzbekistan: results of a nationwide survey, 2010 to 2011.
Ulmasova DJ; Uzakova G; Tillyashayhov MN; Turaev L; van Gemert W; Hoffmann H; Zignol M; Kremer K; Gombogaram T; Gadoev J; du Cros P; Muslimova N; Jalolov A; Dadu A; de Colombani P; Telnov O; Slizkiy A; Kholikulov B; Dara M; Falzon D
Euro Surveill; 2013 Oct; 18(42):. PubMed ID: 24176581
[TBL] [Abstract][Full Text] [Related]
19. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
[TBL] [Abstract][Full Text] [Related]
20. Initial resistance to companion drugs should not be considered an exclusion criterion for the shorter multidrug-resistant tuberculosis treatment regimen.
Lempens P; Decroo T; Aung KJM; Hossain MA; Rigouts L; Meehan CJ; Van Deun A; de Jong BC
Int J Infect Dis; 2020 Nov; 100():357-365. PubMed ID: 32829049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
